Bedrijfsoverzicht
Evaxion A/S is a clinical-stage biotechnology enterprise dedicated to the development and commercialization of artificial intelligence-powered immunology vaccines. Operating within the broader Healthcare sector and the specialized Biotechnology industry, the company focuses on leveraging advanced computational models to design novel therapeutic interventions for oncology. The organization employs a workforce of 46 individuals and holds a total market capitalization of $33.69M, reflecting its status as a small-cap entity in the biopharmaceutical landscape. Its reported annual revenue stands at $7.53M, while its forward P/E ratio of 101.00 suggests that the market prices the stock based on future earnings expectations rather than current profitability. These valuation metrics and revenue figures indicate that the company is positioned in a high-risk, high-potential growth phase where market value is driven primarily by the progress of its clinical pipeline and the perceived future commercial potential of its vaccine candidates, rather than established cash flows.
Financiële gezondheid
The company reported a revenue of $7.53M over the trailing twelve months, yet it recorded a net income of $-7,707,000 and an EBITDA of $-8,873,000. The significant divergence between the positive revenue figure and the substantial negative net income reveals a cost structure characterized by heavy research and development expenditures typical of clinical-stage biotech firms. Free cash flow for the period was $-4,449,750, indicating that the company is currently burning cash to fund its operations and clinical trials, which limits immediate financial flexibility but is a standard strategic necessity for this industry. The financial statements display a gross margin of 100.0%, which is consistent with the sale of intellectual property or early-stage products where the cost of goods sold is negligible compared to the revenue generated. However, the operating margin stands at -122.7% and the profit margin is -102.4%, signaling that operating expenses and overhead costs significantly exceed the revenue generated by the business. On the balance sheet, the company holds $23.23M in cash against $7.50M in debt, resulting in a debt-to-equity ratio of 44.04, which suggests a relatively leveraged position relative to equity but one that is currently supported by a strong cash reserve. The current ratio is 5.85, indicating a robust short-term liquidity position where current assets are more than five times current liabilities, providing ample buffer to meet obligations. Furthermore, the return on equity is -100.2% and the return on assets is -28.2%, metrics that reveal that management is currently generating negative returns on the capital invested by shareholders and held on the books due to the cumulative losses incurred during the clinical development phase.
Waarderingsbeoordeling
The valuation metrics present a complex picture with a trailing P/E ratio listed as N/A due to the lack of positive earnings, while the forward P/E is 101.00. The absence of a trailing P/E implies that the market cannot value the stock based on historical profitability, whereas the forward P/E suggests the market anticipates a significant turnaround or future earnings generation within the next twelve months. The price-to-book ratio is 1.98, indicating that the market values the company at nearly twice its book value, which often reflects the high value placed on the company's intangible assets, such as its patent portfolio and AI-driven vaccine platforms. Alternative valuation multiples further illustrate this premium, with a price-to-sales ratio of 4.48 and an EV/EBITDA of -188.10, suggesting that investors are pricing the stock based on revenue potential and future clinical success rather than current cash profitability. The stock has exhibited significant volatility, trading between a 52-week high of $12.15 and a 52-week low of $1.25. Based on the available data, the current price sits at a point where the valuation is heavily dependent on the trajectory of its clinical trials, as the wide spread between the high and low demonstrates sensitivity to market sentiment regarding biotech outcomes. Additionally, the beta value is 0.20, which indicates that the stock's price volatility is substantially lower than that of the broader market, behaving more like a defensive asset in terms of day-to-day movement despite its high-risk underlying business model.
Growth & Income
The company's revenue growth year-over-year is reported as -100.0%, reflecting a contraction or a reset in reporting periods typical for early-stage biotech entities, while earnings growth is listed as N/A due to negative earnings. The negative revenue growth combined with negative earnings growth implies that the company is in a reinvestment phase where current financial performance is sacrificed to advance the development of its key assets, such as the EVX-01 vaccine for advanced melanoma and the EVX-03 DNA-based cancer vaccine. As a non-dividend payer, the company maintains a dividend yield of N/A and a payout ratio of 0.0%, meaning that all available earnings and cash reserves are retained within the organization to fund ongoing clinical trials and operational expansion rather than being distributed to shareholders. The overall growth and income profile is defined by a complete absence of current profitability and dividend distributions, positioning the company as a pure-play speculative investment reliant entirely on the successful completion of its multi-center clinical trials to unlock future value.